Featured Research

from universities, journals, and other organizations

New weekly fertility injections work as well as daily, study suggests

Date:
June 13, 2012
Source:
Wiley-Blackwell
Summary:
New long-lasting weekly injections of fertility hormones are as safe and effective as standard daily injections, according to Cochrane researchers. The researchers compared weekly and daily hormone injections and found no difference in pregnancies or serious side effects between the two regimens.

New long-lasting weekly injections of fertility hormones are as safe and effective as standard daily injections, according to Cochrane researchers. The researchers compared weekly and daily hormone injections in a Cochrane systematic review and found no difference in pregnancies or serious side effects between the two regimens.

Women undergoing fertility treatment are usually given daily injections of follicle stimulating hormone (FSH) to increase the number of eggs that their ovaries release each month. In in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), the eggs are then removed and fertilised outside the body. Daily hormone injections can be painful and stressful but a new longer-lasting FSH, known as corifollitropin alfa, has recently been introduced. One injection of this longer-lasting hormone can replace the first seven days of FSH injections required in the standard treatment regimen.

The researchers included data from four trials involving 2,335 people in their review. They show that women given medium doses of the new long-lasting hormone on a weekly basis are equally likely to become pregnant and are no more likely to have a miscarriage or ectopic pregnancy than those receiving daily FSH injections.

"These results show that the new long-acting injections are a safe treatment option and equally effective in medium doses compared to the standard daily injections," said Jan Kremer, one of the authors of the review based at the Radboud University Nijmegen Medical Center in Nijmegen, Netherlands.

However, there is currently limited information about patient satisfaction with long-lasting FSH. "One of the main reasons weekly injections are considered preferable to daily injections is that they are more patient friendly," said Kremer. "So are couples undergoing fertility treatment happier with weekly injections? We would like to see research addressing this question."

Further research is also needed to establish whether long-acting injections are as effective in women who respond poorly to fertility hormones and those who 'hyperrespond', meaning they produce higher than expected numbers of eggs.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Annefloor W Pouwer, Cindy Farquhar, Jan AM Kremer. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Library, 2012 DOI: 10.1002/14651858.CD009577.pub2

Cite This Page:

Wiley-Blackwell. "New weekly fertility injections work as well as daily, study suggests." ScienceDaily. ScienceDaily, 13 June 2012. <www.sciencedaily.com/releases/2012/06/120613091049.htm>.
Wiley-Blackwell. (2012, June 13). New weekly fertility injections work as well as daily, study suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/06/120613091049.htm
Wiley-Blackwell. "New weekly fertility injections work as well as daily, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/06/120613091049.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins